Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 11/20 | 0.55 |
| ▸ | DNPH1 | O43598 | 3/20 | 0.51 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.48 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.48 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.48 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.47 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22858552 | 0.93 | P2RY12 (0.47) | P2RY12DNPH1P2RY2P2RY1P2RY6 | |
| SCHEMBL19944484 | 0.93 | P2RY12 (0.47) | P2RY12DNPH1P2RY2P2RY1P2RY6 | |
| SCHEMBL25293 | 0.92 | P2RY12 (0.48) | P2RY12DNPH1P2RY2P2RY1P2RY6 | |
| SCHEMBL20692061 | 0.90 | P2RY12 (0.45) | P2RY12DNPH1P2RY2P2RY1P2RY6 | |
| SCHEMBL19146239 | 0.89 | P2RY12 (0.44) | P2RY12P2RY2P2RY1P2RY6 | |
| SCHEMBL21263848 | 0.89 | P2RY12 (0.44) | P2RY12DNPH1P2RY2P2RY1P2RY6 | |
| SCHEMBL21540034 | 0.89 | P2RY12 (0.44) | P2RY12DNPH1P2RY2P2RY1P2RY6 | |
| SCHEMBL24322092 | 0.88 | P2RY12 (0.43) | P2RY12DNPH1P2RY2P2RY1P2RY6 | |
| SCHEMBL20353076 | 0.88 | P2RY12 (0.45) | P2RY12DNPH1P2RY2P2RY1P2RY6 | |
| SCHEMBL25004 | 0.87 | ABL1 (0.56) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10562929-B2 | Cyclic dinucleotides for cytokine induction | KAYLA THERAPEUTICS (FR) | 2020-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10562929-B2 | Cyclic dinucleotides for cytokine induction | IL1B, IFNG, IFNAR1 | P2RY12 908/4885DNPH1 2540/4885P2RY2 911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.